CORRECTION

Open Access

Correction to: The regulatory ZFAS1/miR-150/ST6GAL1 crosstalk modulates sialylation of EGFR via PI3K/Akt pathway in T-cell acute lymphoblastic leukemia



Qianqian Liu¹⁺, Hongye Ma²⁺, Xiuhua Sun³, Bing Liu¹, Yang Xiao¹, Shimeng Pan¹, Huimin Zhou⁴, Weijie Dong⁵ and Li Jia^{1*}

Correction to: J Exp Clin Cancer Res (2019) 38:199 https://doi.org/10.1186/s13046-019-1208-x

In the original publication of this article [1], there is a mistake in Fig. 4e.

The corrected Fig. 4e should be:

Author details

¹College of Laboratory Medicine, Dalian Medical University, Dalian 116044, 9 Lushunnan Road Xiduan, Dalian 116044, Liaoning Province, China.
²Department of Clinical Laboratory, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital University of Medicine Sciences, Beijing 100010, China.
³Department of Medicine Oncology, Second Affiliated Hospital of Dalian Medical University, Dalian 116027, Liaoning Province, China.
⁴Department of Microbiology, Dalian Medical University, Dalian 116044, Liaoning Province, China.
⁵Department of Biochemistry, Dalian Medical University, Dalian 116044, Liaoning Province, China.

Published online: 16 August 2019

Reference

 Liu Q, et al. The regulatory ZFAS1/miR-150/ST6GAL1 crosstalk modulates sialylation of EGFR via PI3K/Akt pathway in T-cell acute lymphoblastic leukemia. J Exp Clin Cancer Res. 2019;38:199.

* Correspondence: linjian0198@sina.com

[†]Qianqian Liu and Hongye Ma contributed equally to this work. ¹College of Laboratory Medicine, Dalian Medical University, Dalian 116044, 9 Lushunnan Road Xiduan, Dalian 116044, Liaoning Province, China Full list of author information is available at the end of the article



© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which pernits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.



Fig. 1 Upregulation of ST6GAL1 promotes proliferation and chemoresistance in T-ALL cell lines (**a**) qRT-PCR and western blot were carried out to detect ST6GAL1 levels. **b** The expression of FITC-SNA was determined. **c** The viability of cells transfected with ST6GAL1 was determined by CCK8 assay at 0, 24, 48, 72 and 96 h. **d** Enhanced ST6GAL1 facilitated colony formation. **e** Ki67 expression was observed by immunoflourescence, red fluorescence: Ki67, blue fluorescence: DAPI. **f** CCK8 assays were used to measure the resistance to ADR, VCR and Pacliatxel. The absorbance was measured at 450 nm. **g** The IC50 values were calculated. **h** Relative molecular expression of key caspase-dependent apoptosis was analyzed by western blot. **i** The apoptosis rate of different treated cells was analyzed by FCM. ST6GAL1 upregulation inhibited cells survival in response to ADR, j Effects of ST6GAL1 upregulation on tumor growth were shown in vivo. **k** ST6GAL1 and Ki67 expression was observed by IHC staining. Data were means \pm SD of triplicate determinants (**P* < 0.05)